Pharmaceutical

Novartis Q2 2025 Earnings Report Financial statements Novartis Novartis reported strong Q2 2025 results with double-digit revenue growth, key product successes, and promising R&D breakthroughs. The company's innovation and strategic focus position it for sustained long-term leadership.
Global Biopharma Layoffs July 2025 Layoffs Layoff GSK BMS Merck Biopharmaceutical industry sees major July layoffs, with companies like Sarepta, GSK, Century, and Sage Therapeutics cutting jobs amid restructurings, trial setbacks, and M&A activity.
FDA Reconsiders Elevidys Amid Safety Concerns FDA Sarepta The FDA is reevaluating Sarepta's gene therapy Elevidys after a third patient death linked to its treatments. The agency may halt shipments amid rising safety concerns and market fallout.
WuXi AppTec Q2 2025 Earnings Report Financial statements Market Trend WuXi AppTec CDMO U.S. CDMOs face strategic setbacks amid global supply chain shifts, while China, South Korea, and Europe intensify competition in high-growth biotech sectors like CGT and ADC, reshaping the global CDMO landscape.
Trump's Big Beautiful Bill: Impact on US Pharma & Global Healthcare Lessons Pharmaceutical Deep analysis of Trump's healthcare reform bill - how Medicaid cuts, orphan drug exemptions & tax breaks reshape US pharma, with crucial lessons for China's healthcare policy makers.
Chugai Taps Gero's AI in $1B+ Aging R&D Deal Roche Gero Chugai Pharmaceutical Anti-Aging Chugai Pharmaceutical teams up with AI biotech Gero in a $1B+ deal to develop antibody therapies targeting aging-related diseases. The partnership leverages Gero’s AI platform and supports Chugai’s global innovation strategy.
Amarin Partners with Recordati to Reinvigorate European Vascepa Sales Amarin Recordati Amarin licenses European rights to heart drug Vazkepa to Recordati for $25M upfront, aiming to revive sales amid U.S. decline. The deal includes milestones, royalties, and supports Amarin’s strategic restructuring and cost-saving goals.
GSK and Bharat Biotech to Cut Malaria Vaccine Cost GSK Vaccine GSK and Bharat Biotech plan to reduce the cost of Mosquirix, the world’s first WHO-approved malaria vaccine, to under $5 per dose by 2028, aiming to expand global access and support Gavi’s child immunization goals across Africa.
Sanofi and Gilead Expand Protein Degrader Portfolios Sanofi Gilead Sanofi and Gilead deepen their partnerships with Kymera Therapeutics, focusing on next-gen protein degraders for cancer and immune diseases in multi-million dollar deals, signaling rising industry interest.
GSK Strengthens Blenrep's Case with New Data GSK EHA GSK’s Blenrep demonstrates significant progression-free survival improvements in multiple myeloma trials DREAMM-8 and DREAMM-7, strengthening its case for a U.S. market return with FDA decision expected by July 2025.